Type
- Cancellation by sponsor (513)
- ARTG (460)
- Australian public assessment report (AusPar) (69)
- Prescription medicine registration (44)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (1)
Date
- 2026 (4)
- 2025 (38)
- 2024 (86)
- 2023 (73)
- 2022 (59)
- 2021 (124)
- 2020 (107)
- 2019 (98)
- 2018 (95)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (19)
- 2013 (9)
- 2012 (8)
- 2011 (14)
- 2010 (27)
- 2009 (13)
- 2008 (5)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (3)
- 2002 (10)
- 2001 (6)
- 2000 (20)
- 1999 (9)
- 1998 (12)
- 1997 (16)
- 1996 (8)
- 1995 (3)
- 1994 (31)
- 1993 (17)
- 1992 (5)
- 1991 (86)
Sponsor content
1143 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5 mL bivalent vaccine powder for injection vial + diluent vial.
-
Australian public assessment report (AusPar)Ixifi (infliximab) is approved for treatment of several conditions including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease, refractory fistulising Crohn’s disease, and ulcerative colitis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EDRONAX reboxetine 4mg (as mesilate) tablet bottle.
-
Feb-2026Prescription medicine evaluationActive ingredient: palbociclib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled glass syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 3 micrograms/0.3 mL concentrated suspension for injection multidose vial.
-
Australian public assessment report (AusPar)Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors or severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.